Posted by Michael Wonder on 14 May 2022
Hansa Biopharma announces temporary marketing authorisation in Switzerland for Idefirix (imlifidase) in kidney transplantation
13 May 2022 - Idefirix is now granted marketing authorisation within the EU, the U.K., Israel and Switzerland.
Hansa Biopharma today announces that Swissmedic has granted temporary marketing authorisation for Idefirix in adult patients with a positive crossmatch against an available organ from a diseased donor.
The use of Idefirix in Switzerland is reserved for patients with a low probability of being transplanted within the framework of the current national kidney allocation system.
